June 25, 2019
Poxel, Sumitomo Dainippon Pharma’s Type 2 Diabetes combo imeglimin/insulin Phase 3 trial meets primary endpoint
Imeglimin in combination with insulin Phase 3 TIMES 3 16-week, double-blind, placebo-controlled, randomized part of the trial met its primary endpoint with a favorable safety and tolerability profile